Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase 2 4Phase 1/2 2

Status

Completed 3Recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 2Gastrointestinal 2

Conditions

Carcinoma, Non-Small-Cell Lung 18Stomach Neoplasms 16Lung Neoplasms 9Neoplasm Metastasis 5Neoplasms 4Adenocarcinoma 4Colonic Neoplasms 3Carcinoma, Hepatocellular 3Thymoma 2Rectal Neoplasms 2Non-small Cell Lung Cancer Metastatic 2Malignant Solid Tumor 2Esophageal Neoplasms 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Breast Neoplasms 2Urethral Neoplasms 1Ureteral Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Metastatic Small Intestinal Adenocarcinoma 1Mesothelioma, Malignant 1Mesothelioma 1Melanoma 1Liver Neoplasms 1Liver Diseases 1Head and Neck Neoplasms 1

Interventions

Gemcitabine 53Bevacizumab 52Cyclophosphamide 49Docetaxel 42Carboplatin 40pembrolizumab 37Paclitaxel 36Fluorouracil 36Cisplatin 35Radiotherapy 31Oxaliplatin 31Capecitabine 29Irinotecan 28Dexamethasone 27Leucovorin 25Cetuximab 25Nivolumab 24Doxorubicin 22Drug Therapy 21Erlotinib Hydrochloride 20Pemetrexed 19durvalumab 18trametinib 17fludarabine 16atezolizumab 16Trastuzumab 16Sunitinib 16Rituximab 16Prednisone 16Sorafenib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms × Ramucirumab × Clear all
NCT05999994 2026-03-27

CAMPFIRE

Eli Lilly and Company

Phase 2 Recruiting
105 enrolled
Tumor-Agnostic

Neoplasms

NCT01017731 2015-06-10

Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes

Eli Lilly and Company

Phase 2 Completed
68 enrolled 13 charts
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT00627042 2014-10-08

Study of IMC-1121B (Ramucirumab) in Participants With Liver Cancer Who Have Not Previously Been Treated With Chemotherapy

Eli Lilly and Company

Phase 2 Completed
42 enrolled 19 charts
Gastrointestinal

Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms

NCT01246960 2014-10-08

A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer

Eli Lilly and Company

Phase 2 Completed
168 enrolled 16 charts
Gastrointestinal

Esophageal Neoplasms, Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡